Core Viewpoint - Erdene Resource Development Corp. is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, after market hours [1]. Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast on March 25, 2025, at 9:00 AM Eastern Time [2]. - A replay of the webcast will be available for one year after the event [2]. Group 2: Company Overview - Erdene Resource Development Corp. is a Canada-based resource company focused on gold production at the Bayan Khundii Gold Mine in Mongolia [2]. - The company has a portfolio of precious and base metal projects near the Bayan Khundii Gold Mine, indicating a strong organic growth pipeline [2]. - Erdene is listed on the Toronto Stock Exchange (ERD), the Mongolian stock exchange (ERDN), and the OTCQX Market (ERDCF) [2].

Core Viewpoint - Gauzy Ltd. is currently not in compliance with Nasdaq's minimum bid price requirement, having a closing bid price below $1.00 for 30 consecutive business days, but this notification does not impact ongoing operations or trading [1][2][5]. Compliance and Listing Requirements - The company has been granted a 180-calendar-day compliance period until September 14, 2026, to regain compliance with the minimum bid price requirement [3]. - If compliance is not regained by the deadline, Gauzy may be eligible for an additional 180-calendar-day compliance period, provided it meets other listing requirements [4]. Company Operations - The notification from Nasdaq does not affect the company's business operations, strategic initiatives, or the trading of its ordinary shares [5]. - Gauzy intends to monitor its share price and consider options to regain compliance if necessary [5]. Company Overview - Gauzy Ltd. is a fully-integrated company focused on the research, development, manufacturing, and marketing of vision and light control technologies, serving various industries [8]. - The company is headquartered in Tel Aviv, Israel, with subsidiaries in multiple countries, including Germany, France, the United States, and China, and serves leading brands across aeronautics, automotive, and architecture [8].

Core Insights - CapsoVision, Inc. announced a $14 million private placement in public equity financing to support its growth and product development [1][2][4] - The company reported preliminary, unaudited financial results for Q4 and full year 2025, with revenues of $3.9 million for Q4 and $13.6 million for the full year [5][7] Financing Details - The private placement involved the sale of 2,867,089 shares at a price of $4.883 per share, reflecting a 5% discount to the closing price on March 16, 2026 [2][3] - The proceeds from the financing will be allocated for general corporate purposes, including sales and marketing, research and development, and working capital [2][4] Financial Performance - For the fourth quarter of 2025, CapsoVision generated revenue of $3.9 million, while the total revenue for the full year reached $13.6 million [5][7] - As of December 31, 2025, the company had approximately $10.1 million in cash, cash equivalents, restricted cash, and investments [7] Product Development - CapsoVision is focused on advancing its product pipeline, including CapsoCam Colon and CapsoCam UGI, with enhanced AI capabilities aimed at improving gastrointestinal disease detection [4][6] - The company aims to transform the detection and screening of gastrointestinal diseases through its innovative imaging and AI-enabled solutions [6]

Company Overview - Daré Bioscience, Inc. is a health biotech company focused on women's health, aiming to bridge the gap between scientific advancements and practical solutions [3][4] - The company is dedicated to developing evidence-based solutions for various women's health issues, including contraception, menopause, pelvic pain, fertility, vaginal health, and infectious diseases [3][4] Upcoming Events - Daré Bioscience will host a conference call and live webcast on March 26, 2026, at 4:30 p.m. Eastern Time to review its financial results for the year ended December 31, 2025, and provide a company update [1] - Access to the conference call can be made via phone or through a live webcast available on the company's investor relations website [2] Company Mission and Recognition - The company aims to accelerate the development of credible, science-based solutions that adhere to high clinical standards, including randomized controlled trials and peer-reviewed research [4] - Daré Bioscience's leadership has received recognition in the industry, with mentions in Medicine Maker's Power List and Endpoints News' Women in Biopharma, and its CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma [5]

Core Viewpoint - VisionWave Holdings, Inc. has established and fully acquired VisionWave IL Ltd., a wholly owned subsidiary in Israel, to enhance its global operational footprint in advanced engineering and defense innovation [1][3] Group 1: Company Expansion - The formation of VisionWave IL Ltd. marks an initial step in the company's strategic expansion into Israel, a hub for advanced engineering and applied AI technologies [3] - The establishment aims to accelerate development initiatives, strengthen technical capabilities, and enhance execution across VisionWave's strategic programs [3][5] Group 2: Leadership Appointments - Khdoura Sabbagh (Adir Sabag) has been appointed as the CEO and sole director of VisionWave IL Ltd., overseeing operations and business development [2][4] - Oren Attiya will provide financial leadership and CFO-level services to the subsidiary through his consulting firm, ensuring disciplined financial oversight [2][4] Group 3: Strategic Importance - The Israeli subsidiary is expected to support VisionWave's broader initiatives across its technology ecosystem, aligning technical development with commercial opportunities [5] - The expansion is seen as a way to leverage Israel's concentration of high-caliber engineering talent, particularly in areas aligned with VisionWave's core platforms [3][5]

The City of Tallinn has decided to recall Priit Lello and Karolina Ebba Anna Ullman, who were appointed by the City to the company’s Supervisory Council, with effect from 23 March 2026, and to appoint Andrei Korobeinik and Urmas Reinsalu as new members of the Supervisory Council from the same date. Their terms as Supervisory Council members will run until 22 March 2029. Andrei Korobeinik is an IT entrepreneur, a member of the Riigikogu, the Chairman of the Pärnu City Council, and a member of the Centre Part ...

Core Insights - The company will present early preclinical data on its next-generation Emperor Total Artificial Heart at the ACC.26 conference in New Orleans from March 28 to March 30, 2026 [1][3] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which developed the first total artificial heart approved by both the U.S. FDA and Health Canada [1][7] - SynCardia's Total Artificial Heart is the only commercially available artificial heart technology in the U.S. and Canada, with over 2,100 implants performed across 27 countries [7] Product Development - The Emperor Total Artificial Heart is designed as a fully implantable electromechanical system that aims to preserve physiological autoregulation and hemodynamic performance [3][6] - The new system is intended to provide long-term support while improving mobility and quality of life for patients with advanced heart failure [6] Conference Participation - SynCardia will exhibit at booth 2554 during the ACC.26 conference, providing opportunities for attendees to meet with engineering and clinical teams [4][5] - The conference will serve as a platform for discussing the design, development progress, and future clinical direction of the Emperor Total Artificial Heart [5]

Financial Results Announcement - Insight Molecular Diagnostics Inc. will report its fourth quarter 2025 financial results after the market closes on March 26, 2026 [1] - A live Zoom webinar will be held at 2:00 pm PT / 5:00 pm ET on the same day to discuss the financial results, followed by a Q&A session [1] Conference Participation - The CEO Josh Riggs and CFO Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with a presentation scheduled for April 15, 2026 [3] - iMDx management will conduct one-on-one meetings with investors during the conference, encouraging interested investors to contact their Needham sales representative [3] Company Overview - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [4] - The company has several trademarks including GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [4]

Core Insights - Rezolve Ai is pioneering Agentic Commerce for retail, focusing on AI-powered solutions to enhance consumer engagement and digital commerce efficiency [1][2] Group 1: Event Details - The fireside chat featuring Rezolve Ai's CEO Daniel M. Wagner and Microsoft's Vic Miles will take place on March 24, 2026, at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time [1][3] - The discussion will center on the emergence of Agentic Commerce and the strategic partnership between Rezolve Ai and Microsoft [2][3] - A live webcast of the event will be available on the Rezolve Ai Investor Relations website, with a replay posted shortly after [3] Group 2: Investor Engagement - Mr. Wagner will conduct one-on-one meetings with investors during the two-day event [4] - Investors interested in meeting with Rezolve Ai should contact their Roth representative [4] Group 3: Company Overview - Rezolve Ai (NASDAQ: RZLV) specializes in AI-powered solutions aimed at improving customer engagement, operational efficiency, and revenue growth [5] - The company's Brain Suite offers advanced tools that leverage artificial intelligence to optimize processes and enhance decision-making [5]

Core Viewpoint - PEDEVCO Corp. will participate in the 38th Annual Roth Conference from March 22-24, 2026, showcasing its strategic energy projects in the Rocky Mountain region [1][3]. Company Overview - PEDEVCO Corp. is a publicly traded energy company focused on acquiring and developing high-growth energy projects in the United States, with principal assets in the Rockies and the Permian Basin [3]. - The company's key assets include the Rockies Assets located in the D-J Basin of Wyoming and Northern Colorado, as well as the Powder River Basin in Wyoming and assets in the Permian Basin in eastern New Mexico [3]. Investor Engagement - Management will host investor meetings on-site during the Roth Conference, and an updated investor presentation is available on the company's website [2].